Gemigliptin is a new drug developed by Daiichi Sankyo, Inc. It is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, used to treat type 2 diabetes mellitus. Gemigliptin works by inhibiting the activity of DPP-4, an enzyme that breaks down incretins, hormones that help regulate glucose levels in the body. By inhibiting DPP-4, gemigliptin increases the amount of incretins in the body, leading to an increase in insulin production and a decrease in blood glucose levels.
Gemigliptin is taken as a once-daily tablet, which can be taken with or without food. It is usually taken in combination with other diabetes medications, such as metformin or sulfonylureas. It is not usually recommended as a first-line treatment for type 2 diabetes, but may be used in combination with other medications in people who have not responded to other treatments.
To Know More@ https://www.globalinsightservices.com/reports/gemigliptin-market
Gemigliptin has been found to be effective in reducing blood glucose levels in people with type 2 diabetes. In clinical trials, people taking gemigliptin experienced a decrease in HbA1c levels, an important marker of diabetes control, by an average of 0.5-1.1%. Gemigliptin was also found to be well-tolerated, with the most common side effects being upper respiratory tract infections, headache, and diarrhea.
Gemigliptin is a promising new treatment for type 2 diabetes. It has been shown to be effective in reducing blood glucose levels and is generally well-tolerated. However, as with all medications, it is important to discuss risks and benefits with your doctor before starting treatment.
Key Trends
Gemigliptin technology is a relatively new approach to the treatment of type 2 diabetes. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by slowing the breakdown of the incretin hormones GLP-1 and GIP. This allows the body to produce more insulin and use glucose more efficiently. Gemigliptin has been shown to improve glycemic control in patients with type 2 diabetes, and it has a low risk of hypoglycemia.
The key trends in Gemigliptin technology are centered around its potential to improve glycemic control, reduce the risk of hypoglycemia, and provide a more convenient and effective treatment option for patients with type 2 diabetes.
First, Gemigliptin has been shown to improve glycemic control in patients with type 2 diabetes. Studies have demonstrated that Gemigliptin is effective in reducing HbA1c levels, fasting plasma glucose levels, and postprandial glucose levels. In addition, Gemigliptin has been shown to be effective in combination with other diabetes medications, including metformin, sulfonylureas, and thiazolidinediones.
Second, Gemigliptin has a low risk of hypoglycemia. Hypoglycemia is a serious side effect of many diabetes medications, and it can be life-threatening. The low risk of hypoglycemia associated with Gemigliptin makes it a desirable treatment option for patients with type 2 diabetes.
Third, Gemigliptin is convenient and easy to use. It is available in tablet form and can be taken once daily. This makes it easier for patients to adhere to their treatment regimen, which can improve glycemic control.
Finally, Gemigliptin is cost-effective. It is available in generic form, which makes it much less expensive than other diabetes medications. This makes it a viable treatment option for patients who may not be able to afford more expensive medications.
Key Drivers
Gemigliptin is a new drug used to treat type 2 diabetes, and its market is growing rapidly. The key drivers of the Gemigliptin market are the rising prevalence of diabetes, the increasing demand for new and improved treatments, the growing acceptance of new drugs, the growing awareness of diabetes and its complications, and the increasing availability of generic versions of the drug.
The prevalence of diabetes is increasing around the world, and this is one of the main drivers of the Gemigliptin market. According to the World Health Organization (WHO), the number of people living with diabetes has risen from 108 million in 1980 to 422 million in 2014. This increase in the prevalence of diabetes has increased the demand for new and improved treatments such as Gemigliptin, which is a newer and more effective treatment.
Request Sample@ https://www.globalinsightservices.com/reports/tympanometers-market/GIS26306
The growing acceptance of new drugs is another key driver of the Gemigliptin market. As new drugs are developed, they must be tested and approved by regulatory bodies such as the Food and Drug Administration (FDA) before they can be sold to the public. The approval process is lengthy and expensive, but it ensures that drugs are safe and effective for use in the general population. This has led to an increase in the acceptance of new drugs, including Gemigliptin, which has allowed it to become more widely available.
The growing awareness of diabetes and its complications is another key driver of the Gemigliptin market. Diabetes is a serious and potentially life-threatening condition, and it is becoming more widely known that diabetes is a major public health issue. This increased awareness has led to an increase in demand for treatments such as Gemigliptin, which can help to control blood sugar levels and reduce the risk of complications.
Finally, the increasing availability of generic versions of the drug is another key driver of the Gemigliptin market. Generic drugs are copies of brand-name drugs that are made by other manufacturers and are generally cheaper than the brand-name versions. The availability of generic versions of Gemigliptin has made it more affordable for people who need this treatment, increasing the demand for the drug.
Research Objectives
- Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region
- Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling
- Identify factors influencing market growth and challenges, opportunities, drivers and restraints
- Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates
- Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
- Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market
- To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.
- Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives
Request Customization@ https://www.globalinsightservices.com/request-customization/GIS26306
Market Segmentation
The market can be segmented by type of drug, dosage form, distribution channel, and region. By Type of Drug, the market can be divided into Gemigliptin Monotherapy & Gemigliptin Combination Therapy. By Dosage Form, the market can be divided into Gemigliptin Tablets & Gemigliptin Injectable. By Distribution Channel, the market can be divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World.
Key Players
The market includes players such as LG Chem (KOR), Hanmi Pharmaceutical Co., Ltd. (KOR), Boryung Pharmaceutical Co., Ltd. (KOR), Novartis AG (CHE), EirGenix, Inc(TWN), Biocon Limited (IND), L. Pharma GmbH (DEU), Daewoong Pharmaceutical Co., Ltd. (KOR), Sandoz International GmbH (CHE), and Boryung Pharmaceutical Co., Ltd. (KOR).
Buy your copy here@ https://www.globalinsightservices.com/checkout/single_user/GIS26306
Research Scope
- Scope – Highlights, Trends, Insights. Attractiveness, Forecast
- Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others
- Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain
- Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments
- Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis
- Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.
With Global Insight Services, you receive:
10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Infographic excel data pack, easy to analyze big data
- Robust and transparent research methodology
- Unmatched data quality and after sales service
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.